Gujarat Terce Laboratories Limited (GUJTERC) Fair Value & Analysis
Healthcare · IN · Market cap ₹260M
Fair value as of: Jul 5, 2026
From 23 valuation models · updated 3 days ago
Share price −4.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹30.90 – ₹56.58 · fair‑value band ₹33.41 – ₹61.36 · the ₹33.35 price screens below the ₹43.23 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Gujarat Terce Laboratories Limited (GUJTERC) currently trades at ₹33.35, while our model-based Fair Value estimate is ₹43.23 — implying the stock looks roughly 29.6% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Gujarat Terce Laboratories Limited generated revenue of ₹475M at a net margin of 4.6%. Revenue declined 7.5% year over year. It earns a return on equity of 27.2%. Net debt stands at ₹1.6M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹33.41 (bear case) to ₹61.36 (bull case); at ₹33.35, the current price sits below that range. The share trades about 44% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -24% fair-value upside — at 30%, GUJTERC screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Gujarat Terce Laboratories Limited develops, manufactures, markets, and distributes medicines and healthcare products in India and internationally. The company's products include branded generic pharmaceutical covering various therapeutic areas, such as antibiotics, respiratory, nutraceuticals, gastrology, gynecology, pain therapy, and ayurvedic. It provides its products in various forms, including tablets, capsules, oral liquids, ointments, and injections under the Acolate, Tynol, Resplash, Ferlit, Z-Oxi, Vitfol, and Aziter brands. Gujarat Terce Laboratories Limited was incorporated in 1985 and is based in Ahmedabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Gujarat Terce Laboratories Limited reported revenue of ₹475M in FY2026 versus ₹401M in FY2022, a compound +4.3%/yr. Reported net income was ₹22.0M in FY2026, compounding +26.0%/yr from FY2022.
Is GUJTERC fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹991.46 | -47% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gujarat Terce Laboratories Limited (GUJTERC) undervalued?
What is the fair value of GUJTERC?
What is the quality score of GUJTERC?
What is the revenue of Gujarat Terce Laboratories Limited (GUJTERC)?
What is the net profit margin of GUJTERC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.